RPRX
RoyaltyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case: successful tuck-in acquisitions or above-consensus royalty inflows plus benign interest rates lift NAV multiples toward the analyst high; clinical/regulatory milestones for high-value assets are realized, supporting upside to or above the analyst high of $58.8 [#SERP-3].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.5.
What can break
Adverse clinical/regulatory outcomes for key royalty assets
Momentum
80
Value
61
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $46.34 · Bull $58.80 · Bear $38.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $52.43
Why
Momentum80 · Δ7d +1.5
Value61 · Δ7d +0.1
Sentiment37 · Δ7d +1.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
80
34% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
+12.4
Value
61
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
37
33% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+1.2
Why this grade
Composite grade B. Momentum 79.9 / Value 60.8 / Sentiment 37.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$31.1B
Beta
0.41
Shares Out
577.29M
P/E (TTM)
22.7
P/S (TTM)
9.74
P/FCF (TTM)
40.35
Rev YoY
+7.9%
EPS YoY
-45.2%
Gross Margin
-
Op Margin
+65.2%
Net Debt
$5.84B
Current Ratio
3.48
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology